StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15−0.00 (-1.72%)

Close on Nov 18, 2026Market cap $10.06MP/E –Yield –

TScan Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

TScan Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$116.28M. For fiscal 2025 it was -$135.32M. The highest annual figure on record is -$3.02M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$135.32M–
FY2024Dec 31, 2024-$110.82M–
FY2023Dec 31, 2023-$61.36M–
FY2022Dec 31, 2022-$66.50M–
FY2021Dec 31, 2021-$48.68M–
FY2020Dec 31, 2020-$3.02M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$27.54M–
Q1 FY2026Mar 31, 2026-$24.28M–
Q4 FY2025Dec 31, 2025-$32.00M–
Q3 FY2025Sep 30, 2025-$32.46M–
Q2 FY2025Jun 30, 2025-$33.27M–
Q1 FY2025Mar 31, 2025-$37.59M–
Q4 FY2024Dec 31, 2024-$27.41M–
Q3 FY2024Sep 30, 2024-$27.92M-448.2%
Q2 FY2024Jun 30, 2024-$26.23M–
Q1 FY2024Mar 31, 2024-$29.27M–
Q4 FY2023Dec 31, 2023-$23.77M–
Q3 FY2023Sep 30, 2023$8.02M–
Q2 FY2023Jun 30, 2023-$22.02M–
Q1 FY2023Mar 31, 2023-$23.59M–
Q4 FY2022Dec 31, 2022-$16.01M–
Q3 FY2022Sep 30, 2022-$17.00M–
Q2 FY2022Jun 30, 2022-$13.37M–
Q1 FY2022Mar 31, 2022-$20.12M–
Q4 FY2021Dec 31, 2021-$14.38M–
Q3 FY2021Sep 30, 2021-$13.64M–
Q2 FY2021Jun 30, 2021-$10.70M–
Q1 FY2021Mar 31, 2021-$9.96M–
Q4 FY2020Dec 31, 2020-$7.35M–
Q3 FY2020Sep 30, 2020-$5.79M–

More TScan Therapeutics figures

See a number that looks wrong?